A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

This study tests a new virus-based cancer treatment called T3011, given directly into tumors, either alone or combined with the immunotherapy drug pembrolizumab. It is designed for people with advanced cancers including melanoma, head and neck cancer, sarcoma, skin squamous cell cancer, or lung cancer that have not responded to standard treatments. **You may be eligible if...** - You are 18 or older - You have advanced or metastatic melanoma, head and neck squamous cell cancer, sarcoma, cutaneous squamous cell cancer, or non-small cell lung cancer (without EGFR/ALK changes) - Your cancer has progressed on standard treatment - You have at least one tumor that can be injected - You are in generally good health and able to carry out daily activities - You have no active herpes lesions or herpes sores at the time of screening **You may NOT be eligible if...** - All your tumors are located where they cannot be injected - You have brain metastases - You have HIV, active hepatitis B or C - You previously received another oncolytic virus therapy or gene therapy - You have active autoimmune disease or are on immune-suppressing medications - You are pregnant or breastfeeding - You have had a prior organ transplant - You have active heart failure, unstable angina, or serious heart rhythm problems Talk to your doctor to see if this trial is right for you.